RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 I-PRESERVE Trial Fails to Find Clinical Benefit of Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 8
IS 8
SP 18
OP 19
DO 10.1177/155989770900800810
UL http://mdc.sagepub.com/content/8/8/18.abstract
AB Approximately 50% of heart failure (HF) patients have a left ventricular ejection fraction =45%. The majority of them are women and older patients. Unlike low ejection fraction HF, the primary underlying condition in heart failure with preserved ejection fraction (HFPEF) is hypertension. There currently are no evidence-based treatments to improve outcomes in patients with HFPEF. This article presents the results of the Irbesartan in Heart Failure with Preserved Ejection Fraction Study [I-PRESERVE; NCT00095238].